Latest Pharma Insights
CMS Looks To Expand CJR Model Along With Rate Bump In Latest Proposed Rule
Medicare is proposing to expand its Comprehensive Care for Joint Replacement Model, an expired initiative designed to improve care for patients having hip and knee replacements, the most common surgeries among Medicare beneficiaries.
Medtech Insight - April 14, 2026
Medicare is proposing to expand its Comprehensive Care for Joint Replacement Model, an expired initiative designed to improve care for patients having hip and knee replacements, the most common surgeries among Medicare beneficiaries.
Medtech Insight - April 14, 2026
Great Expectations: Icotyde Could Be J&J’s Biggest Product Ever, Duato Says
The oral IL-23 blocker for plaque psoriasis is off to a strong launch and was a focus of the company’s first quarter sales and earnings call.
Scrip - April 14, 2026
The oral IL-23 blocker for plaque psoriasis is off to a strong launch and was a focus of the company’s first quarter sales and earnings call.
Scrip - April 14, 2026
Obsidian Will Go Public Via Merger With Galera And Raise $350m
Deal Snapshot: The deal will leave Obsidian with a Nasdaq listing, majority ownership of the combined company and projected financial runway into late 2028.
Scrip - April 14, 2026
Deal Snapshot: The deal will leave Obsidian with a Nasdaq listing, majority ownership of the combined company and projected financial runway into late 2028.
Scrip - April 14, 2026
FDA Budget Request Reflects $1B Planned CDRH Spending
The FDA’s proposed budget narrative reflects a requested 2027 CDRH budget of just over $1bn, up about $86bn from 2026. The increased funds will be spent on user fee activities and enhanced inspections.
Medtech Insight - April 14, 2026
The FDA’s proposed budget narrative reflects a requested 2027 CDRH budget of just over $1bn, up about $86bn from 2026. The increased funds will be spent on user fee activities and enhanced inspections.
Medtech Insight - April 14, 2026
Eli Lilly To Buy CrossBridge And Its Dual-Payload ADC Tech
The Houston-based biotech has a preclinical TROP2-targeting ADC with Topo1 and ATR payloads planned for an IND filing in 2026.
Scrip - April 14, 2026
The Houston-based biotech has a preclinical TROP2-targeting ADC with Topo1 and ATR payloads planned for an IND filing in 2026.
Scrip - April 14, 2026
‘Scale Matters And Portfolio Matters’ – Biocon’s Erick On The US Biosimilars Market
Matt Erick, chief commercial officer for advanced markets at Biocon Biologics, told Generics Bulletin why he foresees consolidation on the way in the US biosimilars sector – but also why no single company can try and tackle the whole market on its own.
Generics Bulletin - April 14, 2026
Matt Erick, chief commercial officer for advanced markets at Biocon Biologics, told Generics Bulletin why he foresees consolidation on the way in the US biosimilars sector – but also why no single company can try and tackle the whole market on its own.
Generics Bulletin - April 14, 2026
Click Therapeutics Cuts Over 25% Of Staff After $50M Raise, CT-155 Commercial Shift
Click Therapeutics has cut more than a quarter of its workforce as the digital therapeutics developer pivots from research to commercialization. The layoffs follow a $50m Series D investment from Boehringer Ingelheim and a partnership shift.
Medtech Insight - April 14, 2026
Click Therapeutics has cut more than a quarter of its workforce as the digital therapeutics developer pivots from research to commercialization. The layoffs follow a $50m Series D investment from Boehringer Ingelheim and a partnership shift.
Medtech Insight - April 14, 2026
Ofev Rivals Hit US As Five Firms Get FDA Nod
After a recent loss of exclusivity for Boehringer, five companies are set to launch US generic versions for Ofev, a $3.7bn drug targeted for the treatment of idiopathic pulmonary fibrosis.
Generics Bulletin - April 14, 2026
After a recent loss of exclusivity for Boehringer, five companies are set to launch US generic versions for Ofev, a $3.7bn drug targeted for the treatment of idiopathic pulmonary fibrosis.
Generics Bulletin - April 14, 2026
Organon Clears Legal Overhang In Crowded Denosumab Market
Organon and Henlius have settled US patent litigation with Amgen over denosumab biosimilars, months after launching their products, removing legal uncertainty while highlighting intense competition and pricing pressure in an already crowded market.
Generics Bulletin - April 14, 2026
Organon and Henlius have settled US patent litigation with Amgen over denosumab biosimilars, months after launching their products, removing legal uncertainty while highlighting intense competition and pricing pressure in an already crowded market.
Generics Bulletin - April 14, 2026
Evommune Makes Case For MRGPRX2 Inhibition in Migraine
The company's potential pipeline-in-a-product EVO756, which has shown promise in atopic dermatitis and chronic spontaneous urticaria, is now going into a Phase IIb study for migraine.
Scrip - April 14, 2026
The company's potential pipeline-in-a-product EVO756, which has shown promise in atopic dermatitis and chronic spontaneous urticaria, is now going into a Phase IIb study for migraine.
Scrip - April 14, 2026
The 2026 Scrip Awards Is Open For Entries
Entries for the Scrip Awards are now open. Now in their 22nd year, the Awards recognize outstanding achievements across the pharmaceutical, biotech and allied industries in improving human health.
Scrip - April 14, 2026
Entries for the Scrip Awards are now open. Now in their 22nd year, the Awards recognize outstanding achievements across the pharmaceutical, biotech and allied industries in improving human health.
Scrip - April 14, 2026
Travere’s Filspari Is First Drug Approved For FSGS
The US FDA approved the endothelin and angiotensin II receptor antagonist for the rare kidney disorder, presenting a new growth opportunity for the company.
Scrip - April 14, 2026
The US FDA approved the endothelin and angiotensin II receptor antagonist for the rare kidney disorder, presenting a new growth opportunity for the company.
Scrip - April 14, 2026
Henlius Challenges Roche’s Phesgo With First Patient Dosed
Henlius has dosed the first patient in a Phase I trial of HLX319, its subcutaneous pertuzumab/trastuzumab biosimilar to Phesgo. The study marks the first human dosing for the fixed-dose combination in China and underscores Henlius’ push into complex, higher-value oncology biosimilars.
Generics Bulletin - April 14, 2026
Henlius has dosed the first patient in a Phase I trial of HLX319, its subcutaneous pertuzumab/trastuzumab biosimilar to Phesgo. The study marks the first human dosing for the fixed-dose combination in China and underscores Henlius’ push into complex, higher-value oncology biosimilars.
Generics Bulletin - April 14, 2026
Spyre Sees Monotherapy Potential For UC Drug After Phase II Data
Positive Phase II data suggest Spyre’s ?4?7 integrin antagonist could be a viable UC monotherapy, while also strengthening the case for its broader combination strategy.
Scrip - April 14, 2026
Positive Phase II data suggest Spyre’s ?4?7 integrin antagonist could be a viable UC monotherapy, while also strengthening the case for its broader combination strategy.
Scrip - April 14, 2026
Serving Billions, Not Just Selling Products: Bayer’s Consumer Health Strategy
Exclusive: Bayer Consumer Health is betting that ecosystem?led self?care, rather than product?led growth, is the key to serving billions of consumers while delivering economic, social and commercial value, according to head of inclusive growth and global access Caroline Meledo.
HBW Insight - April 14, 2026
Exclusive: Bayer Consumer Health is betting that ecosystem?led self?care, rather than product?led growth, is the key to serving billions of consumers while delivering economic, social and commercial value, according to head of inclusive growth and global access Caroline Meledo.
HBW Insight - April 14, 2026
Belief BioMed’s Deal-Making Playbook For Chinese Rare Disease Drugs
Belief BioMed‘s co-founder and chairman explains a two-pronged approach that Chinese developers of rare disease drugs could use to reach out-licensing deals with global partners.
Scrip - April 14, 2026
Belief BioMed‘s co-founder and chairman explains a two-pronged approach that Chinese developers of rare disease drugs could use to reach out-licensing deals with global partners.
Scrip - April 14, 2026
SynOx Charts Market Path For Emactuzumab After Phase III TGCT Win
SynOx is eyeing a BLA filing for Emactuzumab with the US FDA in the second half of this year.
Scrip - April 14, 2026
SynOx is eyeing a BLA filing for Emactuzumab with the US FDA in the second half of this year.
Scrip - April 14, 2026
In Vivo’s 2026 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the seventh edition of In Vivo's Rising Leaders series.
In Vivo - April 14, 2026
Top 30 leaders: see the list of industry influencers highlighted in the seventh edition of In Vivo's Rising Leaders series.
In Vivo - April 14, 2026
Rising Leaders: Helping EU Device Innovators Clear The Green Agenda’s Hurdles
Attorney at law Jilles van der Hoek co-founded a Green Team within Axon Lawyers to ensure the legal chamber strikes the correct balance between providing support for MDR/IVDR issues and ensuring clients keep their sustainability needs “in sight.”
In Vivo - April 14, 2026
Attorney at law Jilles van der Hoek co-founded a Green Team within Axon Lawyers to ensure the legal chamber strikes the correct balance between providing support for MDR/IVDR issues and ensuring clients keep their sustainability needs “in sight.”
In Vivo - April 14, 2026
Podcast: How Lilly TuneLab Is Breaking Data Silos In Biotech
Eli Lilly’s Aliza Apple, one of In Vivo's 2026 Rising Leaders, explains how TuneLab uses federated learning and shared ADMET/developability models to give early-stage biotechs plug?and?play, privacy?preserving AI for drug discovery.
In Vivo - April 14, 2026
Eli Lilly’s Aliza Apple, one of In Vivo's 2026 Rising Leaders, explains how TuneLab uses federated learning and shared ADMET/developability models to give early-stage biotechs plug?and?play, privacy?preserving AI for drug discovery.
In Vivo - April 14, 2026
Rising Leaders 2026: Christina Coughlin’s Pioneering Immuno-Oncology Career
Avacta’s CEO began as a student of cell therapy architect Carl June, and has since held roles at several of the industry’s most innovative oncology companies.
In Vivo - April 14, 2026
Avacta’s CEO began as a student of cell therapy architect Carl June, and has since held roles at several of the industry’s most innovative oncology companies.
In Vivo - April 14, 2026
In Vivo’s 2026 Rising Leaders
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
In Vivo - April 14, 2026
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
In Vivo - April 14, 2026
Storm Of Interest Could Follow FTC Complaint Alleging False Income Claims By MLM Distributor
Stormy Wellington agrees to proposed settlement prohibiting her from making false and misleading income claims. She not only sells health, wellness and beauty products in MLM but also is an entrepreneur for helping women building their own wealth.
HBW Insight - April 14, 2026
Stormy Wellington agrees to proposed settlement prohibiting her from making false and misleading income claims. She not only sells health, wellness and beauty products in MLM but also is an entrepreneur for helping women building their own wealth.
HBW Insight - April 14, 2026
Great Expectations: Icotyde Could Be J&J’s Biggest Product Ever, Duato Says
The oral IL-23 blocker for plaque psoriasis is off to a strong launch and was a focus of the company’s first quarter sales and earnings call.
Scrip - April 14, 2026
The oral IL-23 blocker for plaque psoriasis is off to a strong launch and was a focus of the company’s first quarter sales and earnings call.
Scrip - April 14, 2026
Obsidian Will Go Public Via Merger With Galera And Raise $350m
Deal Snapshot: The deal will leave Obsidian with a Nasdaq listing, majority ownership of the combined company and projected financial runway into late 2028.
Scrip - April 14, 2026
Deal Snapshot: The deal will leave Obsidian with a Nasdaq listing, majority ownership of the combined company and projected financial runway into late 2028.
Scrip - April 14, 2026
Eli Lilly To Buy CrossBridge And Its Dual-Payload ADC Tech
The Houston-based biotech has a preclinical TROP2-targeting ADC with Topo1 and ATR payloads planned for an IND filing in 2026.
Scrip - April 14, 2026
The Houston-based biotech has a preclinical TROP2-targeting ADC with Topo1 and ATR payloads planned for an IND filing in 2026.
Scrip - April 14, 2026
Evommune Makes Case For MRGPRX2 Inhibition in Migraine
The company's potential pipeline-in-a-product EVO756, which has shown promise in atopic dermatitis and chronic spontaneous urticaria, is now going into a Phase IIb study for migraine.
Scrip - April 14, 2026
The company's potential pipeline-in-a-product EVO756, which has shown promise in atopic dermatitis and chronic spontaneous urticaria, is now going into a Phase IIb study for migraine.
Scrip - April 14, 2026
The 2026 Scrip Awards Is Open For Entries
Entries for the Scrip Awards are now open. Now in their 22nd year, the Awards recognize outstanding achievements across the pharmaceutical, biotech and allied industries in improving human health.
Scrip - April 14, 2026
Entries for the Scrip Awards are now open. Now in their 22nd year, the Awards recognize outstanding achievements across the pharmaceutical, biotech and allied industries in improving human health.
Scrip - April 14, 2026
Travere’s Filspari Is First Drug Approved For FSGS
The US FDA approved the endothelin and angiotensin II receptor antagonist for the rare kidney disorder, presenting a new growth opportunity for the company.
Scrip - April 14, 2026
The US FDA approved the endothelin and angiotensin II receptor antagonist for the rare kidney disorder, presenting a new growth opportunity for the company.
Scrip - April 14, 2026
Spyre Sees Monotherapy Potential For UC Drug After Phase II Data
Positive Phase II data suggest Spyre’s ?4?7 integrin antagonist could be a viable UC monotherapy, while also strengthening the case for its broader combination strategy.
Scrip - April 14, 2026
Positive Phase II data suggest Spyre’s ?4?7 integrin antagonist could be a viable UC monotherapy, while also strengthening the case for its broader combination strategy.
Scrip - April 14, 2026
Belief BioMed’s Deal-Making Playbook For Chinese Rare Disease Drugs
Belief BioMed‘s co-founder and chairman explains a two-pronged approach that Chinese developers of rare disease drugs could use to reach out-licensing deals with global partners.
Scrip - April 14, 2026
Belief BioMed‘s co-founder and chairman explains a two-pronged approach that Chinese developers of rare disease drugs could use to reach out-licensing deals with global partners.
Scrip - April 14, 2026
SynOx Charts Market Path For Emactuzumab After Phase III TGCT Win
SynOx is eyeing a BLA filing for Emactuzumab with the US FDA in the second half of this year.
Scrip - April 14, 2026
SynOx is eyeing a BLA filing for Emactuzumab with the US FDA in the second half of this year.
Scrip - April 14, 2026
CMS Looks To Expand CJR Model Along With Rate Bump In Latest Proposed Rule
Medicare is proposing to expand its Comprehensive Care for Joint Replacement Model, an expired initiative designed to improve care for patients having hip and knee replacements, the most common surgeries among Medicare beneficiaries.
Medtech Insight - April 14, 2026
Medicare is proposing to expand its Comprehensive Care for Joint Replacement Model, an expired initiative designed to improve care for patients having hip and knee replacements, the most common surgeries among Medicare beneficiaries.
Medtech Insight - April 14, 2026
FDA Budget Request Reflects $1B Planned CDRH Spending
The FDA’s proposed budget narrative reflects a requested 2027 CDRH budget of just over $1bn, up about $86bn from 2026. The increased funds will be spent on user fee activities and enhanced inspections.
Medtech Insight - April 14, 2026
The FDA’s proposed budget narrative reflects a requested 2027 CDRH budget of just over $1bn, up about $86bn from 2026. The increased funds will be spent on user fee activities and enhanced inspections.
Medtech Insight - April 14, 2026
Click Therapeutics Cuts Over 25% Of Staff After $50M Raise, CT-155 Commercial Shift
Click Therapeutics has cut more than a quarter of its workforce as the digital therapeutics developer pivots from research to commercialization. The layoffs follow a $50m Series D investment from Boehringer Ingelheim and a partnership shift.
Medtech Insight - April 14, 2026
Click Therapeutics has cut more than a quarter of its workforce as the digital therapeutics developer pivots from research to commercialization. The layoffs follow a $50m Series D investment from Boehringer Ingelheim and a partnership shift.
Medtech Insight - April 14, 2026
Serving Billions, Not Just Selling Products: Bayer’s Consumer Health Strategy
Exclusive: Bayer Consumer Health is betting that ecosystem?led self?care, rather than product?led growth, is the key to serving billions of consumers while delivering economic, social and commercial value, according to head of inclusive growth and global access Caroline Meledo.
HBW Insight - April 14, 2026
Exclusive: Bayer Consumer Health is betting that ecosystem?led self?care, rather than product?led growth, is the key to serving billions of consumers while delivering economic, social and commercial value, according to head of inclusive growth and global access Caroline Meledo.
HBW Insight - April 14, 2026
Storm Of Interest Could Follow FTC Complaint Alleging False Income Claims By MLM Distributor
Stormy Wellington agrees to proposed settlement prohibiting her from making false and misleading income claims. She not only sells health, wellness and beauty products in MLM but also is an entrepreneur for helping women building their own wealth.
HBW Insight - April 14, 2026
Stormy Wellington agrees to proposed settlement prohibiting her from making false and misleading income claims. She not only sells health, wellness and beauty products in MLM but also is an entrepreneur for helping women building their own wealth.
HBW Insight - April 14, 2026
‘Scale Matters And Portfolio Matters’ – Biocon’s Erick On The US Biosimilars Market
Matt Erick, chief commercial officer for advanced markets at Biocon Biologics, told Generics Bulletin why he foresees consolidation on the way in the US biosimilars sector – but also why no single company can try and tackle the whole market on its own.
Generics Bulletin - April 14, 2026
Matt Erick, chief commercial officer for advanced markets at Biocon Biologics, told Generics Bulletin why he foresees consolidation on the way in the US biosimilars sector – but also why no single company can try and tackle the whole market on its own.
Generics Bulletin - April 14, 2026
Ofev Rivals Hit US As Five Firms Get FDA Nod
After a recent loss of exclusivity for Boehringer, five companies are set to launch US generic versions for Ofev, a $3.7bn drug targeted for the treatment of idiopathic pulmonary fibrosis.
Generics Bulletin - April 14, 2026
After a recent loss of exclusivity for Boehringer, five companies are set to launch US generic versions for Ofev, a $3.7bn drug targeted for the treatment of idiopathic pulmonary fibrosis.
Generics Bulletin - April 14, 2026
Organon Clears Legal Overhang In Crowded Denosumab Market
Organon and Henlius have settled US patent litigation with Amgen over denosumab biosimilars, months after launching their products, removing legal uncertainty while highlighting intense competition and pricing pressure in an already crowded market.
Generics Bulletin - April 14, 2026
Organon and Henlius have settled US patent litigation with Amgen over denosumab biosimilars, months after launching their products, removing legal uncertainty while highlighting intense competition and pricing pressure in an already crowded market.
Generics Bulletin - April 14, 2026
Henlius Challenges Roche’s Phesgo With First Patient Dosed
Henlius has dosed the first patient in a Phase I trial of HLX319, its subcutaneous pertuzumab/trastuzumab biosimilar to Phesgo. The study marks the first human dosing for the fixed-dose combination in China and underscores Henlius’ push into complex, higher-value oncology biosimilars.
Generics Bulletin - April 14, 2026
Henlius has dosed the first patient in a Phase I trial of HLX319, its subcutaneous pertuzumab/trastuzumab biosimilar to Phesgo. The study marks the first human dosing for the fixed-dose combination in China and underscores Henlius’ push into complex, higher-value oncology biosimilars.
Generics Bulletin - April 14, 2026
In Vivo’s 2026 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the seventh edition of In Vivo's Rising Leaders series.
In Vivo - April 14, 2026
Top 30 leaders: see the list of industry influencers highlighted in the seventh edition of In Vivo's Rising Leaders series.
In Vivo - April 14, 2026
Rising Leaders: Helping EU Device Innovators Clear The Green Agenda’s Hurdles
Attorney at law Jilles van der Hoek co-founded a Green Team within Axon Lawyers to ensure the legal chamber strikes the correct balance between providing support for MDR/IVDR issues and ensuring clients keep their sustainability needs “in sight.”
In Vivo - April 14, 2026
Attorney at law Jilles van der Hoek co-founded a Green Team within Axon Lawyers to ensure the legal chamber strikes the correct balance between providing support for MDR/IVDR issues and ensuring clients keep their sustainability needs “in sight.”
In Vivo - April 14, 2026
Podcast: How Lilly TuneLab Is Breaking Data Silos In Biotech
Eli Lilly’s Aliza Apple, one of In Vivo's 2026 Rising Leaders, explains how TuneLab uses federated learning and shared ADMET/developability models to give early-stage biotechs plug?and?play, privacy?preserving AI for drug discovery.
In Vivo - April 14, 2026
Eli Lilly’s Aliza Apple, one of In Vivo's 2026 Rising Leaders, explains how TuneLab uses federated learning and shared ADMET/developability models to give early-stage biotechs plug?and?play, privacy?preserving AI for drug discovery.
In Vivo - April 14, 2026
Rising Leaders 2026: Christina Coughlin’s Pioneering Immuno-Oncology Career
Avacta’s CEO began as a student of cell therapy architect Carl June, and has since held roles at several of the industry’s most innovative oncology companies.
In Vivo - April 14, 2026
Avacta’s CEO began as a student of cell therapy architect Carl June, and has since held roles at several of the industry’s most innovative oncology companies.
In Vivo - April 14, 2026
In Vivo’s 2026 Rising Leaders
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
In Vivo - April 14, 2026
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
In Vivo - April 14, 2026